血清miR-200a与过氧化物还原酶水平对晚期三阴性乳腺癌患者预后的预测价值

Prognostic value of serum miR-200a and PRX3 levels in patients with advanced triple negative breast cancer

目的分析血清miR-200a与过氧化物还原酶(PRX3)水平对晚期三阴性乳腺癌患者预后的预测价值。方法选取2021年1月—2022年12月义乌市中心医院收治的80例晚期三阴性乳腺癌患者为研究对象,入选患者均采取相同的化疗方案,并根据化疗效果分为观察组(完全缓解、部分缓解,共计45例)与对照组(稳定、进展,共计35例)。两组均行血清miR-200a与PRX3检测,比较两组检测结果差异;同时根据该组患者有无血清miR-200a、PRX3表达,分为miR-200a阳性组与miR-200a阴性组,PRX3阳性组与PRX3阴性组,比较不同组别无进展生存期、1年存活率的差异;最后通过相关性分析,分析血清miR-200a、PRX3水平与晚期三阴性乳腺癌患者预后情况的相关性。结果观察组与对照组患者血清miR-200a阳性率分别为13.3%和57.1%,血清PRX3阳性率分别为11.1%和51.4%,观察组血清miR-200a与PRX3阳性率均低于对照组(P<0.05);miR-200a阳性组与miR-200a阴性组无进展生存期分别为(6.5±1.8)月和(9.8±2.3)月,1年存活率分别为46.2%和66.7%,miR-200a阳性组的无进展生存期与1年存活率均低于miR-200a阴性组(均P<0.05);PRX3阳性组与PRX3阴性组无进展生存期分别为(6.3±1.5)月和(9.6±2.4)月,1年存活率分别为47.8%和64.9%,PRX3阳性组无进展生存期与1年存活率均低于PRX3阴性组(均P<0.05);通过相关性分析发现,血清miR-200a阳性、PRX3阳性与晚期三阴性乳腺癌患者预后情况存在相关性(r值为5.231、6.854,P值为0.001、0.001)。结论血清miR-200a阳性、PRX3阳性与晚期三阴性乳腺癌患者预后情况存在相关性,血清miR-200a与PRX3阳性的晚期三阴性乳腺癌患者预后情况更差,说明血清miR-200a与PRX3有着较好的预测价值,可推广使用。

Objective To analyze the prognostic value of serum miR-20Oa and PRX3 levels in patients with advanced triple negative breast cancer.Methods 80 patients with advanced triple negative breast cancer from January 2021 to December 2022 were selected.All patients were treated with the same chemotherapy scheme,and were divided into the observation group(45 cases in total with complete remission and partial remission)and the control group(35 cases in total with stable and progressive remission)according to the chemotherapy effect.Both groups were tested for serum miR-20Oa and PRX3,and the differences in test results between the two groups were compared;At the same time,based on the presence or absence of serum miR-200a and PRX3 expression in this group of patients,they were divided into miR-200a positive group and miR-200a negative group,PRX3 positive group and PRX3 negative group.The differences in progression free survival and 1-year survival rates among different groups were compared;Finally,the correlation between serum miR-200a and PRX3 levels and the prognosis of patients with advanced triple negative breast cancer was analyzed by correlation analysis.Results The positive rates of serum miR-200a and PRX3 in the observation group and control group were 13.3%and 57.1%,11.1%and 51.4%,respectively.The positive rates of serum miR-200a and PRX3 in the observation group were lower than those in the control group(P<0.05);The progression free survival time of the miR-200a positive group and the miR-200a negative group were(6.5±1.8)months and(9.8±2.3)months,with 1-year survival rates of 46.2%and 66.7%.The progression free survival time and 1-year survival rate of the miR-200a positive group were lower than those of the miR-200a negative group(P<0.05).The progression free survival time of the PRX3 positive group and the PRX3 negative group were(6.3±1.5)months and(9.6±2.4)months,with 1-year survival rates of 47.8%and 64.9%.The progression free survival time and 1-year survival rate of the PRX3 positive group were lower than those of the PRX3 negative group(P<0.05).Through correlation analysis,it was found that the positive serum miR-20Oa and PRX3 were correlated with the prognosis of advanced triple negative breast cancer patients(r=5.231,6.854,P=0.001,0.001).Conclusion The positive serum miR-200a and PRX3 are correlated with the prognosis of advanced triple negative breast cancer patients.The prognosis of advanced triple negative breast cancer patients with positive serum miR-200a and PRX3 is worse,which indicates that serum miR-200a and PRX3 have good predictive value and can be popularized.